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Introduction MOL #106153 5 2005). Explanations for their apparent 'protean' agonism include biased agonism, differential sensitivity to the stoichiometry and type of available G proteins expressed in the cell background, and/or differences in the level of constitutive activity present in the assay system (Gbahou et al., 2003; Kruger et al., 2005) .
Moreover, and unlike other histamine receptor subtypes, the H 3 R is subject to extensive splicing, yielding a large number of functionally active isoforms (Leurs et al., 2005) . Of these, the full-length isoform, hH 3 R 445 , and the hH 3 R 365 version, are the most highly expressed within the human brain. Both isoforms display distinct localisation profiles, with hH 3 R 445 showing higher expression in the caudate, corpus callosum and spinal cord and hH 3 R 365 being predominant in several areas including the hypothalamus and cerebellum (Bongers et al., 2007) . Interestingly, the 80 amino acid truncation comprises the C-terminal region of IL3 of the full-length receptor, implying that it could mediate differential coupling to intracellular effectors (Huang & Tesmer, 2011) ; a fact consistent with prior, sometimes conflicting, reports of the overall functionality of hH 3 R 365 (Coge et al., 2001; Wellendorph et al., 2002; Esbenshade et al., 2006; Bongers et al., 2007; Arrang et al., 2007) . Surprisingly, given the extensive number of probes and signalling pathways reported for the H 3 R, there has been no systematic analysis of its ability to engender biased agonism, nor the impact of alternative splicing on such bias. Thus, the aim of the current study was to perform a comparative analysis of signalling to various pathways between the key hH 3 R 445 and hH 3 R 365 isoforms, thus focusing not only on "ligand-directed" biased agonism, but also on the potential for "isoform" bias. Strikingly, we identified marked differences in the signalling profile of the two receptor isoforms and notably, clear divergence in the ligand bias profile between the isoforms. Although previous studies have shown that naturally occurring mutations of the calcium-sensing receptor can give rise to differential signalling compared to the wild-type receptor (Leach et al., 2015) , and a very recent paper described splice variant selectivity for the CXCR3 (Berchiche and Sakmar, 2016) , to our knowledge, this is the first This article has not been copyedited and formatted. The final version may differ from this version. 
Materials and Methods

Cell line generation and culture
Stably expressed, tetracycline-inducible, Flp-In-CHO-TREx H 3 R cell lines were generated as previously described by Ward et al., (2011) . Clones were functionally screened for high expression as determined by the efficacy of imetit in 0.5 and 1 µg per mL tetracycline-treated cells in the inhibition of cAMP accumulation assay. Cell lines were maintained in DMEM:
Ham's F-12 1:1 supplemented with 16mM HEPES, 5 μ g per mL blasticidin, 300 μ g per mL hygromycin B and 10% tetracycline free FBS at 37ºC/5% CO 2 .
Membrane preparation
Cells were grown to 80-90 % confluence in 500 cm 2 cell-culture trays at 37ºC/5% CO 2 . All subsequent steps were conducted at 4°C to avoid receptor degradation. The cell-culture medium was removed and ice-cold buffer (10 mL per tray; 10 mM HEPES, 0.9 % w/v NaCl, 0.2 % w/v EDTA, pH 7.4) was added to the cells. The cells were scraped from the trays into a 50 mL Corning tube and centrifuged at 250 x g for 5 min. The supernatant fraction was aspirated and 10 mL per 500 cm 2 tray of wash buffer (10 mM HEPES, 10 mM EDTA, pH 7.4) added to the pellet that was homogenized using an electrical homogenizer 'Werker, ultraturrax' (position 6, 4 x 5 s bursts) and centrifuged at 48,000 x g at 4°C (Beckman Avanti J-251 Ultracentrifuge) for 30 min. The supernatant was discarded and the pellet rehomogenized in wash buffer and centrifuged as described above. The final pellet was suspended in ice-cold assay buffer (10 mM HEPES, 0.1 mM EDTA, pH 7.4) at a concentration of 1-2 mg per mL. Protein concentration was determined by a bicinchoninic acid assay, using BSA as a standard and aliquots maintained at -80°C until required.
[ 3 H]-N-α-methyl histamine binding
All radioligand experiments were conducted in 10 mL tubes, in assay binding buffer (50 mM Tris-HCL, 5 mM EDTA, pH 7.7) and at 25 o C. In all cases non-specific binding (NSB) was This article has not been copyedited and formatted. The final version may differ from this version. AlphaScreen™ SureFire™ Assays -Inhibition of cAMP accumulation, ERK1/2 phosphorylation (pERK1/2) and glycogen synthase kinase (GSK3β) pSer9
The inhibition of cAMP accumulation and activation of pERK1/2 and GSK3β was measured using AlphaScreen™ SureFire™ Assay Kits. Cells were seeded into transparent 96-well plates at 40, 000 cells per well in the presence of 1 μ g per mL tetracycline and incubated overnight at 37ºC/5% CO 2 . For the cAMP assay, cells were washed twice with PBS and incubated in stimulation buffer (phenol red-free DMEM (GIBCO), 1% BSA and 1 mM 3-isobutyl-1-methylxanthine), 37ºC/5% CO 2 for 1 h. pERK1/2 assay using the time to peak as the agonist exposure time (generally 3 -4 min).
These responses were terminated by the removal of drugs and addition of either 100 μ L (pERK1/2) or 25 μ L (GSK3β) SureFire™ lysis buffer, and plates were agitated on a plate shaker for 5 min. To determine agonist activity a volume of 5 μ
μ L (GSK3β) cell lysate was added to a white Proxiplate™, followed by 10 μ
GSK3β) of 100:600:3:3 v/v/v/v mixture of SureFire activation buffer/SureFire reaction buffer/AlphaScreen donor/acceptor beads. All plates were secured with a top-seal. cAMP plates were incubated at 22 o C overnight; pERK1/2 plates were incubated at 37ºC/5% CO 2 for 1 h, and the GSK3β plates were incubated at 22ºC for 2 h. All plates were incubated in the dark and fluorescence measured using a Fusion-Alpha or Envision microplate reader (PerkinElmer, MA) using standard AlphaScreen settings.
[Ca
2+ ] i -mobilization assays
Assays were performed in isotonic buffer (150 mM NaCl, 2.6 mM KCl, 2.2 mM CaCl 2 , 1.18 mM MgCl 2 , 10 mM D-glucose, 10 mM HEPES, 4 mM probenecid and 0.5 % w/v BSA, pH 7.4). Assay buffer was prepared as a [10x] stock (without probenecid or BSA), sterile filtered and stored at 4 °C until required. A [1x] stock (500 mL) of assay buffer was prepared by adding 50 mL of 10x stock and 5 mL of 400 mM probenecid (dissolved in 1 M NaOH) to 440 mL H 2 0, and pH adjusted to 7.4, before making up the final volume to 500 mL. BSA (0.5 % w/v) was added and [1x] assay buffer stored at 4°C for up to two weeks.
Cells were seeded into 96-well plates in growth medium at a density of 40, 000 cells per well and treated with 1 µg per mL final tetracycline. The following day, plates containing a confluent monolayer of cells were washed twice with 100 μ L assay buffer, before being loaded with 100 μ L assay buffer containing 0.9 μ M Fluo-4-AM. After 1 h incubation at 37ºC/5% CO 2 , Fluo-4-AM containing buffer was removed and wells washed twice with 100 μ L assay buffer, before being loaded with 180 μ L assay buffer. After 20 min, compounds were added on a Flexstation microplate reader (Molecular Devices; Sunnyvale, California).
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Label free technology (Cell impedance)
Experiments were conducted on a RTCA SP xCELLigence instrument (ACEA Biosciences) maintained at 37ºC/5% CO 2 . Briefly, a blank read of 100 μ L per well of medium was taken.
Cells were seeded onto a 96-well E-plate at 20, 000 cells per well in the presence of 1 μ g per mL tetracycline and allowed to settle for 30 min before replacing in the machine and monitoring every 2 min and then hourly overnight. Cells were washed with 100 μ L per well PBS and 180 μ L per well serum free medium added. Cells were then monitored every 15 sec for 1 h upon the addition of agonists at varying concentrations. Calculating the area under the cell impedance curves using the RTCA software 1.2, generated agonist concentrationresponse curves using medium only wells as baseline.
Compounds and reagents
All compounds were supplied from Sigma Aldrich, Castle Hill, Australia (R-α-methylhistamine, N-α-methylhistamine); Servier, Paris, France (imetit, proxyfan), or synthesized in-house (iodoproxyfan; as described in Stark et al., 1996) . Radioligands were supplied by Perkin Elmer, Melbourne, Australia. Cell culture and molecular biology reagents were supplied by Life Technologies, Melbourne, Australia.
Data analysis
Saturation binding isotherms were analysed by non-linear regression according to a hyperbolic, one-site binding model, and individual estimates for total receptor number (B max )
where Y is the response measured. E max denotes maximal asymptotic response and Basal denotes minimal asymptotic response.
The analysis of the same datasets to quantify biased agonism can be undertaken in a number of ways; transducer ratios (Log(τ/K A )), relative activity (RA) ratios (ΔLog(E max /EC 50 )) and relative potency ratios (ΔpEC 50 ; Kenakin et al., 2012) . As not all ligands were full agonists in each system (necessary for simple calculation of relative potency ratios), relative transducer ratios were used as the measure of bias. Data from each individual experiment for each pathway were fitted to an equation that directly estimates Log(τ/K A ) and avoids propagation of error associated with fitting individual E max and EC 50 values using the standard Hill equation:
This article has not been copyedited and formatted. The final version may differ from this version. where E m is the maximal response of the system, Basal is the level of the response in the absence of agonist, K A denotes the equilibrium dissociation constant of the agonist A; τ/K A (determined as a logarithm; Christopoulos, 1998) is a composite parameter sufficient to describe agonism and bias for a given pathway, i.e., stimulus-biased agonism can result from either a selective affinity (K A ) of an agonist for a given receptor state(s) and/or a differential coupling efficacy (τ) toward certain pathways, where τ is an index of the signalling efficacy of the agonist (defined as R T /K E , where R T is the total number of receptors and K E is the coupling efficiency of each agonist-occupied receptor), and n is the slope of the transducer function.
To remove system bias, Log(τ/K A ) values were normalised to the reference agonist RαMH.
The Δ Log(τ/K A ) value was determined for each ligand for each pathway was normalized to the RαMH response in the same pathway, according to the following equation:
To account for the differences in expression (R T ) of hH 3 R 365 and hH 3 R 445 , 
The standard error of the mean (SEM) for each Δ Δ Log(τ/K A ) value were calculated as before:
values were compared according to a two-way ANOVA (with assay and agonist as the two group variables) with multiple planned comparisons using Tukey's test (i) between pathways for the same agonist and (ii) between agonists for the same pathway.
To investigate whether any agonist, at anyway pathway, was biased towards either of the two receptor isoforms, Δ Log(τ/K A ) values were calculated using the following equation: values were compared to a theoretical value of zero (i.e. no isoform bias) using a one-sample T-test.
Principal component analysis (PCA) was subsequently applied to the calculated
bias values obtained in eq. 8 for both isoforms, using singular value decomposition as implemented in the package scikit-learn (Pedregosa et al., 2011) . This analysis is a dimensionality reduction method that uses transformations to project a high-dimensional set
This article has not been copyedited and formatted. The final version may differ from this version. of data into a lower dimensional set of variables, called principal components (PCs) (Thompson et al., 2015) . The extracted PC values contain important information from the data, revealing its internal structure in a way that best explains its variance (Wold et al., 1987) . PCs are ranked according to the percentage of total variance in the data they explain.
PC1 explains the maximal total variance found within the data. The subsequent PC values represent the remaining variation, without being correlated with the preceding components.
The script used for the analysis and plotting can be found at https://github.com/thomascoudrat/pca_analysis.
Results
Expression and assay development for histamine H 3 receptor isoforms
To compare the pharmacology of the two most abundantly expressed human histamine H 3 receptor isoforms, CHO-TREx cell lines stably expressing either hH 3 R 365 or hH 3 R 445 were generated.
[ This article has not been copyedited and formatted. The final version may differ from this version. However, imetit, proxyfan and iodoproxyfan yielded more variable responses, with different rank orders of activity across assays and partial agonist versus full agonist behaviours (Figures 2 & 3) . Agonist responses at both receptor isoforms were quantitatively assessed using the transducer ratio method (Kenakin et al., 2012) to determine biased agonism both within and between isoforms.
Evaluation of biased agonism at the full-length histamine H 3 receptor
For both isoforms RαMH was used as the reference agonist to calculate Δ Log(τ/K A ) values (Tables 1 & 2 Figure   5c ).
Perhaps unsurprisingly, proxyfan, the 'protean' agonist of the histamine H 3 receptor, displayed a much more varied profile; it was significantly biased away from the inhibition of cAMP, trending in the same direction for calcium mobilization, ERK1/2 phosphorylation and GTPγ 35 S binding. Given the relative lack of activity to inhibit cAMP accumulation, when the data were normalised to this pathway, proxyfan displayed marked bias towards GSK3β phosphorylation (260-fold), changes in cellular impedance (28-fold) and ERK1/2 phosphorylation (6.6-fold; Table 1 ; Figure 5C ). Iodoproxyfan also displayed significant bias towards a change in cell impedance, a response that was itself significantly different to its ability to inhibit forskolin-stimulated cAMP accumulation at the hH 3 R 445 isoform. When normalised to the latter, marked bias towards changes in cellular impedance (150-fold) and
GSK3β phosphorylation (33-fold) were evident (Table 1; Figure 5C ).
Evaluation of biased agonism at the IL3 deleted histamine H 3 receptor
Our subsequent study sought to determine whether the 80 amino acid deleted receptor, hH 3 R 365 could also mediate biased agonism. Overall, this isoform appeared more permissive in its signalling than the full-length receptor (Figures 4 & 5 ; Table 2 ). Two-way ANOVA of Table 2 revealed a highly significant effect of agonists (P < 0.0001) and assay (P < 0.0001), but also a very significant interaction between the two variables (P = 0.0008), an effect absent at hH 3 R 445 (P = 0.22; Figure 4 ).
Although NαMH displayed no substantial differences compared to the reference agonist RαMH, the profiles of imetit, proxyfan and iodoproxyfan were highly divergent, confirming the presence of significant bias downstream of the receptor ( Figure 4B ; Supplementary Table 2 ). Accordingly, their activity relative to RαMH was fixed to an arbitrary Δ Log(τ/K A ) value of -3.0. This extreme bias away from calcium mobilization for proxyfan and its congener was notable as it was the only functional endpoint for which either compound displayed bias relative to RαMH (all other pathways, bar pERK1/2 for proxyfan, were significantly different to the fixed Δ Log(τ/K A ) values of -3.0 for both agonists; Figure 4B ). Even when normalised to cAMP as a reference pathway, only iodoproxyfan exhibited any other biased agonism, being biased away from ERK1/2 phosphorylation (0.04-fold; Table 2 ; Figures 4B & 5B, D) .
The histamine H 3 receptor exhibits 'isoform bias'
Although both the full length and 80 amino acid deleted H 3 R mediate biased agonism, it remained to be determined whether the direction and magnitude of the bias was conserved between isoforms. Strikingly, none of the agonists stimulated GSK3β phosphorylation via hH 3 R 365 , a pathway readily activated by the hH 3 R 445 isoform, indicating that the hH 3 R 365 isoform is highly biased away from this endpoint (though no quantification was possible due to the lack of activity of any ligand).
Even for pathways activated by both isoforms, visual inspection of the "webs of bias" in Figure 5 suggests that the pharmacology of the hH 3 R 445 and hH 3 R 365 isoforms is different. In order to test this assertion, Log(τ/K A ) values for each agonist in each assay at hH 3 R 365 were subtracted from the corresponding values at the hH 3 R 445 isoform ( Figure 6 ). A value that is This article has not been copyedited and formatted. The final version may differ from this version. (Figure 6 ). Given the subtle differences in localisation and function of the two major isoforms of the H 3 receptor, choice of agonist could influence the observed response(s) and may represent a novel route to selective pharmacology.
To ensure that receptor desensitization or internalization did not markedly influence the bias analysis across the two isoforms, concentration response curves to each agonist were constructed at varying incubation times using the cAMP assay (data not shown). At the 10 min time point that we routinely used for agonist incubations, only minimal desensitisation was observed for both receptor isoforms, and appeared comparable for all agonists tested (% response to 10 μM agonist compared to the 2 min time point, ranging from 76.4 ± 1.8 to 87.6 ± 5.6 and 82.2 ± 6.1 to 92.2 ± 2.3 for the hH 3 R 445 and hH 3 R 365 isoforms respectively;
Supplementary Figure 
Principal component analysis
The bias factors (ΔΔLog(τ/K A )) for the two receptor isoforms were then subjected to PCA, a dimensionality reduction method, to reveal values in the dataset that contribute variability between ligands. Ligands that display similar behaviour cluster together. At hH 3 R 445 , NαMH clustered most closely with RαMH (in PC1), clearly separated from proxyfan, and to a lesser This article has not been copyedited and formatted. The final version may differ from this version. ( Figure 5C ).
Consistent with the more variable pharmacology and permissive signalling of hH 3 R 365, there was no evidence of ligand clustering, suggesting that all ligands produce different bias profiles at this isoform, again correlating with their corresponding bias plots ( Figure 5D ; Figure 7B ). Indeed, comparison of the two principal component analysis plots intuitively reveals the "isoform bias" that exists between hH 3 R 445 and hH 3 R 365.
Discussion
Although the histamine H 3 receptor has long been a therapeutic target of considerable interest, its ability to engender biased signalling has not been comprehensively investigated. Herein we have demonstrated that not only can agonists give rise to biased signalling ("liganddirected bias"), but that two most abundant human H 3 R splice variants (hH 3 R 445 and hH 3 R 365 )
engender different responses ("isoform bias").
The regioisomeric agonists, RαMH and NαMH, display similar pharmacology with no bias at the hH 3 R 445 isoform. The structurally related agonist, imetit, also had a similar profile, though analysis revealed bias towards phosphorylation of GSK3β and ERK1/2. Strikingly, proxyfan, as well its congener iodoproxyfan, produce clearly divergent signalling at the full-length H 3 R with marked bias towards GSK3β phosphorylation and changes in cellular impedance (Figures 4 & 5) . Their distinct profile, both compared to the histamine analogues as well as each other, is reflected in a PCA of the bias factors ( Figure 7A ).
This article has not been copyedited and formatted. The final version may differ from this version. The quantitative confirmation of biased agonism with proxyfan (and iodoproxyfan) helps to explain previous studies that have variously described proxyfan as an inverse agonist, antagonist, partial agonist or full agonist due to its context-dependent pharmacology (Gbahou et al., 2003; Krueger et al., 2005) . This compound's protean agonism has been previously attributed to the degree of constitutive receptor activity present in the assay system under test (Bongers et al., 2007; Morisset et al., 2000) . However, in our studies constitutive activity was only evident at hH 3 R 445 in the inhibition of cAMP accumulation and GTPγ 35 S binding assays (data not shown), suggesting that constitutive activity does not appear to influence the bias that proxyfan engenders.
The second aim of this study was to determine the bias profile of the most abundant isoform of the histamine H 3 receptor, hH 3 R 365 . This splice variant was also subject to biased agonism; notably neither proxyfan nor iodoproxyfan stimulated calcium mobilization via hH 3 R 365 , despite robust responses to NαMH and RαMH ( Figure 3 ; Table 2 ). Overall, the profiles of imetit, proxyfan and iodoproxyfan across the endpoints tested were distinct both to NαMH, RαMH and each other, confirming that this isoform is permissive in its signalling, an assertion supported by the lack of clustering of ligands in the PCA ( Figure 7B ) and the highly significant interaction between ligands and assays in the two-way ANOVA of the Δ The latter is emerging as a key consideration in GPCR discovery, rationalising in vivo efficacy, drug duration of action and selectivity (Riddy et al., 2015; Hoffmann et al., 2015; Copeland, 2016) . More recent studies have also implicated the kinetics of signalling as a key component of biased agonism (Klein Herenbrink et al., 2016) . Given that the assays described herein measure endpoints that range from 15 seconds (calcium mobilization) to 60 minutes (cellular impedance), temporal differences could underlie the observed signalling profiles for proxyfan and iodoproxyfan. Previous studies have shown that intrinsic efficacy of muscarinic M 3 receptor (mAChR) agonists correlate with their dissociation rates; agonists that displayed slow dissociation had higher efficacy in calcium mobilization and GTPγ 35 S binding assays (Sykes et al., 2009) . Therefore, the bias profiles of proxyfan and iodoproxyfan could be due to differential receptor binding kinetics when compared to the simpler histamine analogues, though determination of such properties is beyond the scope of this study. Interestingly, the different lengths of incubation of the signalling assays presented here could explain why the observed bias at the hH 3 R 445 isoform in this study contrasts with that of Schnell et al., (2010) , in which the same agonists displayed no bias when assessed by steady-state GTPase activity with various co-expressed G proteins in Sf9 insect cells.
Log(τ/K
Further to the identification of biased agonism at H 3 R splice variants, we then sought to compare the bias profiles of the two isoforms (appropriately corrected for differences in receptor expression). Unexpectedly, there was a striking difference in signalling between the two major splice variants, which we have termed "isoform bias". Despite the absence of 80 amino acids in the third intracellular loop in hH 3 R 365 (Bongers et al., 2007; Leurs et al., 2005) and the importance of this region in G protein coupling (O'Dowd et al., 1988) This striking "isoform bias" between the two variants was quantified by calculation of the difference in Log(τ/K A ) values for each agonist at each pathway, and revealed a general preference for imetit to activate pathways downstream of the hH 3 R 365 isoform, with iodoproxyfan and proxyfan favouring the full length receptor (Figure 6 ).
The cause of the differential pharmacology between hH 3 R 445 and hH 3 R 365 isoforms is not clear; previous studies using G protein-coupled inward rectifier potassium channel (GIRK) activation as a surrogate of receptor activation showed that the hH 3 R 365 isoform yielded GIRK responses with a 5-6-fold increase in deactivation kinetics compared to hH 3 R 445 , implying that agonists may have a slower off-rate from this isoform (Sahlholm et al., 2012) . It could also be that the kinetic rate(s) of GDP/GTP exchange may differ between isoforms (Dror et al.,
2015
). An alternative explanation could be that the differences arise due to a change in the distances between transmembrane (TM) domains 5 and 6 between isoforms. Kruse et al., (2012) demonstrated, using all known inactive GPCR structures, that the distance between the bases of TM5 and TM6 of Gα i/o -coupled receptors ranged between 12.5 and 14.5Å, whilst, for Gα s -coupled receptors this distance was shorter, ranging from 10 to 12Å. The distance between TM5 and TM6 for the hH 3 R 365 isoform may be reduced, resulting in a receptor that differentially couples to G protein isoforms, in turn activating different signalling networks.
Irrespective of mechanism, the "isoform bias" identified is potentially of therapeutic relevance. Previous studies have extended analysis of biased signalling to naturally occurring mutant variants of the G protein-coupled calcium-sensing receptor, demonstrating significant changes in the signalling profile that, in part, account for their role in various endocrine diseases (Leach et al., 2015) . These data demonstrated that even single amino acid changes result in different receptor conformation that give rise to biased signalling. Unsurprisingly
This article has not been copyedited and formatted. The final version may differ from this version. therefore, the more significant changes in amino acid sequence resulting from gene splicing for the H 3 R readily yields change in biased signalling profile. Nevertheless, we believe that this is the first example of differential signalling mediated by splice variants of the same G protein-coupled receptor. Given that these histamine receptor isoforms have subtly different expression profiles in the brain, further experiments are required to determine whether the observed bias links to CNS diseases -for example in which both GSK3β and the histamine H 3 receptor have been implicated, such as schizophrenia and Alzheimer's disease (Hooper et al., 2008; DaRocha-Souto et al., 2012; Cole, 2013) . Studies in rat tissue have suggested that the well-described auto-receptor function of the histamine H 3 receptor to control histamine release may be mediated primarily by a truncated isoform (Gbahou et al., 2012) , implying that the hH 3 R 365 isoform could play this role in humans. If this were to be the case, the differential activation of downstream effector systems may have evolved to be an autoreceptor-specific mechanism; the data herein offer the possibility that it might be possible to design drugs that selectively target individual H 3 R isoforms. This also may have implications for other receptors for which known variants exist and biased agonism or allosteric modulation has been previously documented e.g. dopamine D 2 receptors (Shonberg et al., 2013; Weichert et al., 2015) and mGlu5 receptors (Noetzel et al., 2013; Rook et al., 2015) .
In summary, a cross-wise evaluation of five agonists at multiple signalling pathways downstream the two main histamine H 3 receptor isoforms clearly identified significant liganddirected biased signalling, most notably for proxyfan, corroborating previous studies describing this compound as a protean agonist. However, even more striking was the identification of "isoform bias" in our study, to our knowledge the first quantitative evidence of this phenomenon in the GPCR field. Whilst the aetiology of the differential bias is not yet clear, it may help guide future discovery efforts targeting the histamine H 3 receptor.
This article has not been copyedited and formatted. The final version may differ from this version. (Table 1) . Grouped data are shown ± SEM (n=3-7). (Table 2) . Grouped data are shown ± SEM (n=3-8). between the two variables (P = 0.0008). For Tukey's planned comparisons testing: * P < 0.05, ** P < 0.01, *** P < 0.001 between agonists for the same assay; ^ P < 0.05, ^^ P < 0.01, ^^^ P < 0.001 between assays for the same agonist. This article has not been copyedited and formatted. The final version may differ from this version. Logτ/K A (normalized to cAMP), values for the hH 3 R 445 isoform as determined from the different signaling assays. Data are expressed as mean ± SEM from a single fit to grouped data of the indicated number (N=) of individual experiments, and n is the transducer slope determined from shared analysis. Values in parentheses were used to plot the webs of bias presented in Figure 5 . NaMH were separated by rapid vacuum filtration using a FilterMate TM Cell Harvester (Perkin Elmer, Melbourne, Australia) onto 96-well GF/B filter mats presoaked with 0.3% PEI and rapidly washed three times with ice cold wash buffer (50 mM Tris-HCL, 5 mM EDTA, pH 7.7). After drying (>1 h), filter mats were separated and placed into scintillation vials. To these 2 mL of Ultima Gold (Perkin Elmer, Melbourne, Australia) was added and radioactivity quantified using a liquid scintillation spectrometry, LS 6500 scintillation counter (Beckman Coulter, High Wycombe, UK). Aliquots of [ 3 H]-NaMH were also quantified accurately to determine how much radioactivity was added to each well. In all experiments, total binding never exceeded more than 10 % of that added, limiting complications associated with depletion of the free radioligand concentration. Grouped data are shown ± SEM (n=3). 
